Intravenous Immune Globulin Versus Intravenous Anti-D Immune Globulin for the Treatment of Acute Immune Thrombocytopenic Purpura

Overview

Journal Indian J Pediatr

Specialty Pediatrics

Date 2009 Feb 5

PMID 19190878

Citations 7

Authors

Elham Shahgholi

Parvaneh Vosough

Kambiz Sotoudeh

Khadijeh Arjomandi

Shahla Ansari

Soraya Salehi

Mohammad Faranoush

Mohammad Ali Ehsani

Affiliations

Soon will be listed here.

Abstract

Objective: The purpose of this study was to compare the efficacy and side effects of intravenous immunoglobulin (IVIG) with intravenous anti-D immunoglobulin for treatment of newly diagnosed acute childhood Idiopathic thrombocytopenic purpura (ITP).

Methods: Children (6 months to 14 years) with newly diagnosed acute ITP and platelet count below 20,000/ microL were randomized to receive single dose intravenous 75 microg/kg anti-D or 1g/kg IVIG for two consecutive days (total dose 2 g/kg). Response rate defined as a platelet count over 20,000 / microL 72 hours after initial treatment.

Results: Eighty one patients (52 male and 29 female) with mean age of 5 years and 3 months randomly divided in anti-D group (n=42) and IVIG group (n=39). Mean baseline (pretreatment) platelet counts were 15406 / microL and 15230/ microL in anti-D and IVIG group, respectively. The response rate in IVIG group (98%) was more significant than anti-D group (76%); (P = 0.017). After 7 days the platelet counts of all patients in IVIG group were more than 20,000/ microL while in anti-D group 12% had platelet counts below 20,000/ microL.

Conclusion: In acute childhood ITP, initial treatment with IVIG (2g/Kg in divided dose) increased platelet count more rapidly and more significant than intravenous anti-D (single dose of 75 microg/kg) within the first 72 hours.

Citing Articles

Phase 3 randomised trial of eltrombopag versus standard first-line pharmacological management for newly diagnosed immune thrombocytopaenia (ITP) in children: study protocol.

Shimano K, Grace R, Despotovic J, Neufeld E, Klaassen R, Bennett C BMJ Open. 2021; 11(8):e044885.

PMID: 34452956 PMC: 8404450. DOI: 10.1136/bmjopen-2020-044885.

American Society of Hematology 2019 guidelines for immune thrombocytopenia.

Neunert C, Terrell D, Arnold D, Buchanan G, Cines D, Cooper N Blood Adv. 2019; 3(23):3829-3866.

PMID: 31794604 PMC: 6963252. DOI: 10.1182/bloodadvances.2019000966.

Management of immune thrombocytopenia: Korean experts recommendation in 2017.

Jang J, Kim J, Mun Y, Bang S, Lim Y, Shin D Blood Res. 2018; 52(4):254-263.

PMID: 29333401 PMC: 5762735. DOI: 10.5045/br.2017.52.4.254.

[Clinical effect of anti-D immunoglobulin in treatment of childhood immune thrombocytopenia: a Meta analysis].

Qin W, Huang S, Li T Zhongguo Dang Dai Er Ke Za Zhi. 2017; 19(10):1070-1076.

PMID: 29046203 PMC: 7389273.

Guidelines on the treatment of primary immune thrombocytopenia in children and adolescents: Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular Guidelines Project: Associação Médica Brasileira - 2012.

Loggetto S, Braga J, Verissimo M, Bernardo W, Medeiros L, Hoepers A Rev Bras Hematol Hemoter. 2014; 35(6):417-27.

PMID: 24478609 PMC: 3905825. DOI: 10.5581/1516-8484.20130124.

References

Bussel J, Graziano J, Kimberly R, Pahwa S, Aledort L . Intravenous anti-D treatment of immune thrombocytopenic purpura: analysis of efficacy, toxicity, and mechanism of effect. Blood. 1991; 77(9):1884-93. View

Blanchette V, Imbach P, Andrew M, Adams M, McMillan J, Wang E . Randomised trial of intravenous immunoglobulin G, intravenous anti-D, and oral prednisone in childhood acute immune thrombocytopenic purpura. Lancet. 1994; 344(8924):703-7. DOI: 10.1016/s0140-6736(94)92205-5. View

Sandler S . Intravenous Rh immune globulin for treating immune thrombocytopenic purpura. Curr Opin Hematol. 2001; 8(6):417-20. DOI: 10.1097/00062752-200111000-00017. View

. Guidelines for the investigation and management of idiopathic thrombocytopenic purpura in adults, children and in pregnancy. Br J Haematol. 2003; 120(4):574-96. DOI: 10.1046/j.1365-2141.2003.04131.x. View

George J, Woolf S, Raskob G, Wasser J, Aledort L, Ballem P . Idiopathic thrombocytopenic purpura: a practice guideline developed by explicit methods for the American Society of Hematology. Blood. 1996; 88(1):3-40. View

Tarantino M, Young G, Bertolone S, Kalinyak K, Shafer F, Kulkarni R . Single dose of anti-D immune globulin at 75 microg/kg is as effective as intravenous immune globulin at rapidly raising the platelet count in newly diagnosed immune thrombocytopenic purpura in children. J Pediatr. 2006; 148(4):489-94. DOI: 10.1016/j.jpeds.2005.11.019. View

Bierling P, Godeau B . Intravenous immunoglobulin and autoimmune thrombocytopenic purpura: 22 years on. Vox Sang. 2004; 86(1):8-14. DOI: 10.1111/j.0042-9007.2004.00391.x. View

Kumar M, Vik T, Johnson C, Southwood M, Croop J . Treatment, outcome, and cost of care in children with idiopathic thrombocytopenic purpura. Am J Hematol. 2005; 78(3):181-7. DOI: 10.1002/ajh.20295. View

NEWTON Jr W, ZUELZER W . Idiopathic thrombopenic purpura in childhood. N Engl J Med. 1951; 245(23):879-85. DOI: 10.1056/NEJM195112062452302. View

10.

Benesch M, Kerbl R, Lackner H, Berghold A, Schwinger W, Triebl-Roth K . Low-dose versus high-dose immunoglobulin for primary treatment of acute immune thrombocytopenic purpura in children: results of a prospective, randomized single-center trial. J Pediatr Hematol Oncol. 2003; 25(10):797-800. DOI: 10.1097/00043426-200310000-00011. View

11.

Warrier I, Bussel J, Valdez L, Barbosa J, Beardsley D . Safety and efficacy of low-dose intravenous immune globulin (IVIG) treatment for infants and children with immune thrombocytopenic purpura. Low-Dose IVIG Study Group. J Pediatr Hematol Oncol. 1997; 19(3):197-201. DOI: 10.1097/00043426-199705000-00004. View

12.

Newman G, Novoa M, Fodero E, Lesser M, Woloski B, Bussel J . A dose of 75 microg/kg/d of i.v. anti-D increases the platelet count more rapidly and for a longer period of time than 50 microg/kg/d in adults with immune thrombocytopenic purpura. Br J Haematol. 2001; 112(4):1076-8. DOI: 10.1046/j.1365-2141.2001.02627.x. View

13.

Gaines A . Acute onset hemoglobinemia and/or hemoglobinuria and sequelae following Rh(o)(D) immune globulin intravenous administration in immune thrombocytopenic purpura patients. Blood. 2001; 95(8):2523-9. View

14.

Cines D, Blanchette V . Immune thrombocytopenic purpura. N Engl J Med. 2002; 346(13):995-1008. DOI: 10.1056/NEJMra010501. View

15.

Godeau B, Caulier M, Decuypere L, Rose C, Schaeffer A, Bierling P . Intravenous immunoglobulin for adults with autoimmune thrombocytopenic purpura: results of a randomized trial comparing 0.5 and 1 g/kg b.w. Br J Haematol. 1999; 107(4):716-9. DOI: 10.1046/j.1365-2141.1999.01766.x. View

16.

Godeau B, Lesage S, Divine M, Wirquin V, Farcet J, Bierling P . Treatment of adult chronic autoimmune thrombocytopenic purpura with repeated high-dose intravenous immunoglobulin. Blood. 1993; 82(5):1415-21. View

17.

De Mattia D, Del Principe D, Del Vecchio G, Jankovic M, Arrighini A, Giordano P . Acute childhood idiopathic thrombocytopenic purpura: AIEOP consensus guidelines for diagnosis and treatment. Associazione Italiana di Ematologia e Oncologia Pediatrica. Haematologica. 2000; 85(4):420-4. View

18.

Blanchette V, Luke B, Andrew M, Barnard D, de Veber B, Gent M . A prospective, randomized trial of high-dose intravenous immune globulin G therapy, oral prednisone therapy, and no therapy in childhood acute immune thrombocytopenic purpura. J Pediatr. 1993; 123(6):989-95. DOI: 10.1016/s0022-3476(05)80400-7. View

19.

Scaradavou A, Woo B, Woloski B, Cunningham-Rundles S, Ettinger L, Aledort L . Intravenous anti-D treatment of immune thrombocytopenic purpura: experience in 272 patients. Blood. 1997; 89(8):2689-700. View

20.

Blanchette V, Carcao M . Intravenous immunoglobulin G and anti-D as therapeutic interventions in immune thrombocytopenic purpura. Transfus Sci. 1999; 19(3):279-88. DOI: 10.1016/s0955-3886(98)00042-3. View